13F reference period
Q3 2026
Security Snapshot
EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX) Institutional Ownership
CUSIP: 29842P105
13F Institutional Holders and Ownership History from Q2 2024 to Q3 2026
Institutions Reporting
25
Shares (Excl. Options)
6.54M
Full value: 6,540,140 · shares · 30 Sep 2026Price
$9.10
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares, no par value
- Symbol
- EPRX on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 6,540,140
- Total 13F value
- $59,295,548
- Portfolio coverage rank
- 0%
- Share change
- +352,259
- Value change
- +$3,249,380
- Number of holders
- 25
- Shares outstanding
- 61,607,578
- SEC-reported price per share
- $7.32
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- EPRX - EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value is tracked under CUSIP 29842P105.
- 25 institutions reported positions in Q3 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 67 to 25 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$163.57M
Full value: $163,566,041 · USD · 30 Jun 2026.$59.3M
Full value: $59,295,548 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 25 institutions filings for Q3 2026.
Security key
29842P105
13F reference period
Q3 2026
13F holders
25
13D/G owners
4
CIK / CUSIP context first
Open Q3 2026 holders
EPRX full holder history
EUPRAXIA PHARMACEUTICALS INC. SEC filings
EUPRAXIA PHARMACEUTICALS INC. company facts
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29842P105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
EPRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Freedman Joseph S. | 9% | -12% | $47,037,881 | +$2,495,500 | 5,843,215 | +5.6% | Joseph S. Freedman | 13 Mar 2026 |
| Beutel, Goodman & Co Ltd. | 8% | $23,947,504 | 4,058,899 | Beutel, Goodman & Co Ltd. | 30 Sep 2025 | |||
| DISBROW ROBERT | 7% | $21,052,085 | 3,568,150 | Robert Disbrow | 30 Sep 2025 | |||
| MANCHESTER MANAGEMENT CO LLC | 4.5% | -40% | $19,184,600 | -$8,600,916 | 2,772,341 | -31% | JAMES E. BESSER | 30 Jun 2026 |
As of 30 Sep 2026,
25
institutional investors reported holding
shares of
EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX).
This represents
11%
of the company’s total
outstanding shares.
6.54M
Full value: 6,540,140 · shares · 30 Sep 202661.61M
Full value: 61,607,578 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
11%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 2.8% | 1,716,320 | +4% | 0.89% | $15,618,512 |
| SCOTIA CAPITAL INC. | 2.3% | 1,425,065 | +6.1% | 0.04% | $12,918,717 |
| Vivo Capital, LLC | 2.2% | 1,350,000 | 0% | 1.4% | $12,285,000 |
| PICTON MAHONEY ASSET MANAGEMENT | 0.56% | 344,001 | -4.7% | 0.03% | $3,130,410 |
| Aisling Capital Management LP | 0.53% | 325,000 | 0% | 0.99% | $2,957,500 |
| CIBC WORLD MARKET INC. | 0.35% | 218,677 | -6.8% | 0% | $1,996,496 |
| FLPUTNAM INVESTMENT MANAGEMENT CO | 0.27% | 167,394 | 0.02% | $1,523,285 | |
| MARSHALL WACE, LLP | 0.26% | 158,133 | 0% | 0% | $1,439,011 |
| BNP PARIBAS FINANCIAL MARKETS | 0.21% | 131,809 | 0% | $1,199,462 | |
| Delaney Capital Management Ltd. | 0.18% | 112,400 | -4.1% | 0.16% | $1,029,092 |
| Qube Research & Technologies Ltd | 0.14% | 88,188 | +158% | 0% | $802,511 |
| TD Waterhouse Canada Inc. | 0.13% | 79,704 | +0.12% | 0% | $561,264 |
| INGALLS & SNYDER LLC | 0.12% | 75,450 | +10% | 0.02% | $687,000 |
| Annis Gardner Whiting Capital Advisors, LLC | 0.1% | 60,000 | 0% | 0.08% | $546,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.09% | 53,010 | +46% | 0% | $482,391 |
| RAYMOND JAMES FINANCIAL INC | 0.09% | 52,439 | -2% | 0% | $477,195 |
| 1832 Asset Management L.P. | 0.08% | 50,432 | 0% | 0% | $458,931 |
| Stonepine Capital Management, LLC | 0.06% | 40,000 | -8% | 0.3% | $364,000 |
| AXQ CAPITAL, LP | 0.03% | 19,174 | -9.3% | 0.02% | $174,483 |
| China Universal Asset Management Co., Ltd. | 0.03% | 16,000 | +28% | 0.01% | $132,880 |
| MORGAN STANLEY | 0.03% | 15,528 | +606% | 0% | $141,305 |
| Magnetar Financial LLC | 0.02% | 12,252 | 0% | $111,493 | |
| NATIXIS | 0.02% | 11,927 | -32% | 0% | $106,389 |
| TCI Wealth Advisors, Inc. | 0.02% | 11,000 | 0% | 0% | $100,100 |
| Northwest & Ethical Investments L.P. | 0.01% | 6,237 | 0% | 0% | $52,121 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Headline period
Q3 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 6,540,140 | $59,295,548 | +$3,249,380 | $9.10 | 25 |
| 2026 Q2 | 24,801,324 | $163,566,041 | +$9,063,683 | $6.61 | 67 |
| 2026 Q1 | 22,228,584 | $158,258,957 | +$59,698,825 | $7.24 | 54 |
| 2025 Q4 | 13,830,451 | $104,211,571 | +$5,872,102 | $7.55 | 35 |
| 2025 Q3 | 12,813,323 | $75,287,324 | +$63,953,992 | $5.90 | 27 |
| 2025 Q2 | 1,970,076 | $10,889,810 | -$1,049,985 | $5.76 | 14 |
| 2025 Q1 | 2,167,593 | $7,087,336 | +$1,118,946 | $3.28 | 11 |
| 2024 Q4 | 1,826,270 | $5,634,759 | +$50,501 | $3.17 | 9 |
| 2024 Q3 | 1,798,968 | $4,545,745 | +$185,000 | $2.63 | 8 |
| 2024 Q2 | 1,727,190 | $4,433,025 | +$4,433,025 | $2.58 | 8 |